Impact of COVID-19 on Cardiovascular Testing in the United States Versus the Rest of the World

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

DOI

  • Cole B. Hirschfeld, Columbia University
  • ,
  • Leslee J. Shaw, Cornell University
  • ,
  • Michelle C. Williams, University of Edinburgh
  • ,
  • Ryan Lahey, Columbia University
  • ,
  • Todd C. Villines, University of Virginia
  • ,
  • Sharmila Dorbala, Harvard University
  • ,
  • Andrew Choi, George Washington University
  • ,
  • Nishant R. Shah, Brown University
  • ,
  • David A. Bluemke, University of Wisconsin-Madison
  • ,
  • Daniel S. Berman, Cedars-Sinai Medical Center
  • ,
  • Ron Blankstein, Harvard University
  • ,
  • Maros Ferencik, Oregon Health and Science University
  • ,
  • Jagat Narula, Icahn School of Medicine at Mount Sinai
  • ,
  • David Winchester, University of Florida
  • ,
  • Eli Malkovskiy, Columbia University
  • ,
  • Benjamin Goebel, Cornell University
  • ,
  • Michael J. Randazzo, Columbia University
  • ,
  • Juan Lopez-Mattei, University of Texas MD Anderson Cancer Center
  • ,
  • Purvi Parwani, Loma Linda University Health
  • ,
  • Joao V. Vitola, Quanta Diagnostico por Imagem
  • ,
  • Rodrigo J. Cerci, Quanta Diagnostico por Imagem
  • ,
  • Nathan Better, Royal Melbourne Hospital
  • ,
  • Paolo Raggi, University of Alberta
  • ,
  • Bin Lu, Chinese Academy of Medical Sciences
  • ,
  • Vladimir Sergienko, RAS - USSR Cardiology Research Center
  • ,
  • Valentin Sinitsyn, Lomonosov Moscow State University
  • ,
  • Takashi Kudo, Nagasaki University
  • ,
  • Bjarne Linde Nørgaard
  • ,
  • Pál Maurovich-Horvat, Semmelweis University
  • ,
  • Yosef A. Cohen, Technion-Israel Institute of Technology
  • ,
  • Thomas N.B. Pascual, Philippines Nuclear Research Institute
  • ,
  • Yaroslav Pynda, International Atomic Energy Agency
  • ,
  • Maurizio Dondi, International Atomic Energy Agency
  • ,
  • Diana Paez, International Atomic Energy Agency
  • ,
  • Rodrigo Cerci
  • ,
  • INCAPS COVID Investigators Group

Objectives: This study sought to quantify and compare the decline in volumes of cardiovascular procedures between the United States and non-U.S. institutions during the early phase of the coronavirus disease-2019 (COVID-19) pandemic. Background: The COVID-19 pandemic has disrupted the care of many non-COVID-19 illnesses. Reductions in diagnostic cardiovascular testing around the world have led to concerns over the implications of reduced testing for cardiovascular disease (CVD) morbidity and mortality. Methods: Data were submitted to the INCAPS-COVID (International Atomic Energy Agency Non-Invasive Cardiology Protocols Study of COVID-19), a multinational registry comprising 909 institutions in 108 countries (including 155 facilities in 40 U.S. states), assessing the impact of the COVID-19 pandemic on volumes of diagnostic cardiovascular procedures. Data were obtained for April 2020 and compared with volumes of baseline procedures from March 2019. We compared laboratory characteristics, practices, and procedure volumes between U.S. and non-U.S. facilities and between U.S. geographic regions and identified factors associated with volume reduction in the United States. Results: Reductions in the volumes of procedures in the United States were similar to those in non-U.S. facilities (68% vs. 63%, respectively; p = 0.237), although U.S. facilities reported greater reductions in invasive coronary angiography (69% vs. 53%, respectively; p < 0.001). Significantly more U.S. facilities reported increased use of telehealth and patient screening measures than non-U.S. facilities, such as temperature checks, symptom screenings, and COVID-19 testing. Reductions in volumes of procedures differed between U.S. regions, with larger declines observed in the Northeast (76%) and Midwest (74%) than in the South (62%) and West (44%). Prevalence of COVID-19, staff redeployments, outpatient centers, and urban centers were associated with greater reductions in volume in U.S. facilities in a multivariable analysis. Conclusions: We observed marked reductions in U.S. cardiovascular testing in the early phase of the pandemic and significant variability between U.S. regions. The association between reductions of volumes and COVID-19 prevalence in the United States highlighted the need for proactive efforts to maintain access to cardiovascular testing in areas most affected by outbreaks of COVID-19 infection.

OriginalsprogEngelsk
TidsskriftJACC: Cardiovascular Imaging
Vol/bind14
Nummer9
Sider (fra-til)1787-1799
Antal sider13
ISSN1936-878X
DOI
StatusUdgivet - sep. 2021

Bibliografisk note

Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Se relationer på Aarhus Universitet Citationsformater

ID: 222565529